Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2023 | Management of temporal arteritis

Bruno Gran, MD, PhD, FRCP, The University of Nottingham, Nottingham, UK, describes the management of temporal arteritis. Corticosteroids remain the primary modality of treatment to date and have been shown to prevent blindness and suppress disease activity. Initiation of corticosteroids shall be considered as soon as possible in suspected cases. Regarding tocilizumab, the time of initiation varies across countries, with some allowing its use from the start while others can only use it in relapsing disease. This interview took place at the 17th World Congress on Controversies in Neurology (CONy) in Dubrovnik, Croatia.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Gran has received personal compensation for consultancy from Merck, Roche, Biogen, Teva UK, and GW Pharma

Dr Gran has received unrestricted research grants from Biogen Idec, Merck, Bayer Healthcare, Teva UK, Novartis, and Genzyme

Dr Gran has received support for the attendance of clinical and research conferences from Biogen, Merck, Bayer Healthcare, Teva UK, Novartis, Genzyme, and CelGene